Qiagen Considers Sale as Takeover Interest Returns
Qiagen is reviewing strategic options, including a possible sale, as takeover interest resurfaces in the fast-growing life sciences and diagnostics sector.
/ 2 items
Qiagen is reviewing strategic options, including a possible sale, as takeover interest resurfaces in the fast-growing life sciences and diagnostics sector.
QIAGEN announces its $225 million acquisition of Parse Biosciences, expanding into scalable single-cell technologies to power AI-driven biological research and drug discovery.